Literature DB >> 11472365

Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein.

C Trambas1, Z Wang, M Cianfriglia, G Woods.   

Abstract

Several lines of evidence including reverse transcription polymerase chain reaction, immunoreactivity and their ability to efflux rhodamine 123 have implied the existence of P-glycoprotein in natural killer (NK) cells. It has been a natural tendency to assume that NK-cell P-glycoprotein is identical to the P-glycoprotein of multidrug resistant (MDR) cell lines, however, the present study uncovered major differences. Functionally, NK cells demonstrated a restricted substrate profile, being unable to transport daunorubicin and calcein acetoxymethylester while efficiently transporting other P-glycoprotein substrates. Furthermore, physical differences in NK-cell P-glycoprotein were established by differential reactivity with P-glycoprotein antibodies. NK cells demonstrated strong reactivity with C494 and JSB-1, but did not react appreciably with C219. In addition, NK cells were unable to bind to the antibody MM4.17 unless they had been fixed and permeabilized, yet this antibody normally recognizes an extracellular epitope of P-glycoprotein. These differences culminated in the demonstration using Western analysis that NK cells did not express detectable levels of 170 kDa P-glycoprotein. Instead, NK cells expressed small-molecular-weight 'mini P-glycoprotein' products, of approximately 70 and 80 kDa. Collectively, these data indicate that the predominant P-glycoprotein species of NK cells are novel mini P-glycoproteins and not the classic P-glycoprotein of MDR models.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472365     DOI: 10.1046/j.1365-2141.2001.02885.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Characterization of the human MDR1 gene.

Authors:  Miklos Bodor; Edward J Kelly; Rodney J Ho
Journal:  AAPS J       Date:  2005-02-16       Impact factor: 4.009

Review 2.  NK cell lymphoma.

Authors:  Kazuo Oshimi
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 3.  Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.

Authors:  Ritsuro Suzuki
Journal:  Int J Hematol       Date:  2010-12-01       Impact factor: 2.490

Review 4.  NK/T-cell lymphomas: pathobiology, prognosis and treatment paradigm.

Authors:  Ritsuro Suzuki
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

Review 5.  Leukemia and lymphoma of natural killer lineage cells.

Authors:  Kazuo Oshimi
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 6.  Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy.

Authors:  Kathleen Köck; Markus Grube; Gabriele Jedlitschky; Lena Oevermann; Werner Siegmund; Christoph A Ritter; Heyo K Kroemer
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.

Authors:  Claudia C Wagner; Martin Bauer; Rudolf Karch; Thomas Feurstein; Stephan Kopp; Peter Chiba; Kurt Kletter; Wolfgang Löscher; Markus Müller; Markus Zeitlinger; Oliver Langer
Journal:  J Nucl Med       Date:  2009-11-12       Impact factor: 10.057

8.  Identification and characterization of primate P-glycoprotein.

Authors:  Mesfin Yimam
Journal:  J Pharmacol Pharmacother       Date:  2015 Jul-Sep

9.  A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.

Authors:  Rong Liang; Guang-Xun Gao; Jie-Ping Chen; Ji-Shi Wang; Xiao-Min Wang; Yun Zeng; Qing-Xian Bai; Tao Zhang; Lan Yang; Bao-Xia Dong; Hong-Tao Gu; Mi-Mi Shu; Cai-Xia Hao; Jian-Hong Wang; Na Zhang; Xie-Qun Chen
Journal:  Hematol Oncol       Date:  2016-10-10       Impact factor: 5.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.